查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870233

脈絡膜新生血管市場：依療法、藥物類別、疾病類型、病變類型、治療階段、通路和最終用戶分類－2025-2032年全球預測

Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，脈絡膜新生血管市場將成長至 116.9 億美元，複合年成長率為 7.85%。

關鍵市場統計數據
基準年 2024 63.8億美元
預計年份：2025年 68.8億美元
預測年份 2032 116.9億美元
複合年成長率 (%) 7.85%

對脈絡膜新生血管（CNV）進行清晰全面的概述：系統性說明其臨床特徵、診斷技術進展和不斷發展的治療現狀。

脈絡膜新生血管（CNV）是影響脈絡膜-視網膜介面最嚴重的併發症之一，可導致視力喪失、長期併發症以及醫療資源的浪費。本文摘要了CNV的臨床特徵、診斷流程以及影響其臨床和商業格局的當代診療標準。多模態影像和早期檢測技術的進步使得更及時的干涉成為可能，從而能夠重建患者病史，改變疾病進展軌跡和治療結果。然而，這些診斷技術的進步也增加了眼科醫師、視網膜專家和門診手術中心之間診療協調的複雜性。

從多學科觀點探討科學、臨床和治療模式的變革性轉變，這些轉變正在重塑脈絡膜新生血管（CNV）的治療範式和相關人員的期望。

在科學創新、醫療服務模式變革以及對以患者為中心的治療結果的重新關注的推動下，脈絡膜新生血管（CNV）的治療格局正在經歷變革性變化。抗血管內皮生長因子（VEGF）藥物的生物學改進和分子工程改造，提高了療效並改善了安全性，促使臨床醫生重新考慮給藥間隔和隨訪方案。同時，真實世界數據和基於註冊登記的見解，為治療提供了更精準的指南，尤其適用於疾病形態複雜或對一線治療反應不佳的患者。這些臨床趨勢與營運模式的改變密切相關。雖然門診手術中心和眼科診所越來越具備進行複雜玻璃體內注射治療的能力，但醫院系統在嚴重病例的治療中仍發揮核心作用。

CNV Therapeutics公司2025年美國關稅環境對供應鏈韌性、製造地和商業協議影響的策略分析

2025年美國關稅調整的累積影響正在改變CNV療法及相關醫療設備的成本結構與供應鏈動態。進口生物製藥原料、包裝材料和專用給藥裝置的關稅調整增加了部分製造商的採購成本，並促使他們重新檢視籌資策略。因此，一些公司正在加快關鍵生物製藥生產流程的在地化進程，並實現供應商多元化，涵蓋多個地區，以降低貿易政策波動帶來的風險。這種供應鏈重組可能會導致前置作業時間延長和短期庫存失衡，因此需要積極主動的庫存管理和分銷計劃。

透過深度細分分析，將治療類型、分子類別、病理/疾病表現型、臨床環境和通路聯繫起來，從而指導可行的臨床和商業策略。

細分分析揭示了治療方案、分子分型、臨床症狀、病變特徵、治療線、分銷管道和終端用戶類型如何共同塑造需求趨勢和治療路徑。治療類型仍然是關鍵因素，其中抗VEGF療法主導治療決策。阿維西普和雷珠單抗等藥物之間的分子差異會影響給藥間隔和患者追蹤。Bevacizumab由於其在某些情況下的成本驅動作用而仍然重要，而具有改進分子結構的新型藥物旨在提高療效和安全性。動態療法與抗VEGF藥物的聯合治療選擇性地用於某些難治性或非典型病例，而基於維替泊芬的獨立動態療法在某些病變亞型中仍然發揮作用。

從區域策略觀點出發，協調全球主要醫療區域在脈絡叢新生血管（CNV）治療方面存在的臨床實踐差異、監管差異和供應鏈現實問題。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管路徑和商業模式均有顯著影響。在美洲，先進的視網膜護理基礎設施和都市區對創新技術的積極應用正在塑造市場發展，而支付方的複雜性和報銷政策的不均衡則造成了不同的准入途徑，需要製定量身定做的市場進入策略。同時，歐洲、中東和非洲地區的管理體制和醫療保健資金籌措模式各不相同，有些市場正在快速接受生物製藥，而有些市場則受到預算上限的限制。應對這些差異需要各國採取相應的措施，並收集證據以支持報銷申請。亞太地區呈現出複雜的格局，龐大的患者群體和不斷成長的專科醫生能力與採購慣例、價格敏感度和監管時限的差異並存。在地化生產和區域夥伴關係是商業性成功的關鍵因素。

公司層面的競爭動態強調分子創新、真實世界數據、病患計劃和供應鏈韌性，以此作為 CNV 差異化的基礎。

公司層面的關鍵趨勢集中在分子設計、生命週期管理和患者支援基礎設施的創新。研發人員正在開發新一代抗VEGF藥物，以延長療效、最佳化安全性，並透過獨特的作用機制和給藥方式實現差異化。策略重點包括建立可靠的真實世界證據項目以證明藥物的相對療效，建立全面的患者支持和依從性服務，以及投資於生產冗餘以降低供應風險。隨著創新公司尋求簡化產品獲取途徑並克服處理複雜生物製藥相關的物流挑戰，它們與專業經銷商和醫院系統之間的合作變得日益重要。

為促進CNV成功，產業領導者可提出的切實可行的優先建議：協調證據產生、生產韌性、准入計畫和支付方參與。

為了將本報告的研究結果轉化為實際營運優勢，產業領導者應優先考慮一系列切實可行的舉措，使臨床差異化與商業性執行相契合。首先，應將實證研究的重點放在頭對頭研究和真實世界對比研究上，以明確不同病變亞型和治療方案的治療定位。此類證據將有助於改善與支付方的溝通，並增強臨床醫生的信心。其次，應投資於靈活的生產製造和區域灌裝包裝能力，以降低關稅引發的供應中斷風險，並縮短關鍵物料的前置作業時間。第三，應根據每個通路和終端用戶的實際情況，量身定做准入和患者援助計劃，並確保門診手術中心和眼科診所獲得所需的後勤和教育支持，從而最佳化患者依從性和治療效果。

本分析所依據的調查方法是一種混合方法研究，它將主要相關利益者訪談與系統的二手證據審查相結合，並採用嚴格的檢驗和品管。

本分析的調查方法融合了第一手和第二手研究手段，以確保其穩健性、有效性和實用性。第一手研究包括對視網膜專科醫生、醫院藥屋主任、診所管理人員和支付方進行半結構式訪談，以收集有關治療決策、運作限制和就醫難的第一手資料。第二手研究包括對同儕審查的臨床文獻、監管申報文件、臨床試驗註冊庫和已發布的專業學會指南進行系統性回顧，以梳理治療模式和特異性病理的治療結果。資料三角驗證法將定性研究結果與已發表的臨床檢驗相結合，以驗證新出現的主題並識別臨床試驗人群與真實世界實踐之間的差異。

整合臨床創新、業務永續營運和支付方合作策略，進行權威分析，將CNV治療進展轉化為持續的患者和商業性效益。

總之，脈絡膜新生血管仍是一個科學和商業性快速發展的領域，臨床創新、供應鏈策略和支付方合作的交匯點將決定患者的治療機會和治療效果。抗VEGF生物製劑和輔助性治療的進步正在推動更個人化的治療模式，但這些機會必須輔以對實證醫學、生產韌性和有針對性的准入計畫的投入。關稅趨勢和區域監管的複雜性增加了營運風險，企業可以透過採購多元化、區域夥伴關係和積極的支付方策略來降低這些風險。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧影像分析技術應用於早期CNV檢測與監測
  • 開發一種緩釋型玻璃體內植入，以減輕脈絡膜新生血管患者的治療負擔
  • 針對血管內皮生長因子路徑治療CNV的基因編輯療法的出現
  • 提高生物相似抗 VEGF 藥物的使用率，以提高 CNV 治療的成本效益和可近性。
  • 引入遠距眼科平台，用於遠端監測和管理脈絡膜新生血管（CNV）進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 脈絡膜新生血管市場依治療方法分類

  • 抗 VEGF 療法
    • 阿黃曲普
    • Bevacizumab
    • 布羅盧西珠單抗
    • 康柏西普
    • 雷珠單抗
  • 聯合治療
    • 動態療法+抗VEGF療法
  • 動態療法
    • 維替泊芬

9. 脈絡膜新生血管市場（依藥物類別分類）

  • 融合蛋白
  • 單株抗體

第10章 脈絡膜新生血管市場依疾病類型分類

  • 新生血管性老齡化黃斑部病變（AMD）
  • 病理性近視

第11章 脈絡膜新生血管市場（依病變類型分類）

  • 經典 CNV
  • 混合拷貝數變異
  • 潛在拷貝數變異

第12章 脈絡膜新生血管市場依治療線分類

  • 一線治療
  • 二級治療
  • 三線治療

第13章 脈絡膜新生血管市場依通路分類

  • 醫院藥房
  • 零售藥房

第14章 脈絡膜新生血管市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 眼科診所

第15章 脈絡膜新生血管市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 脈絡膜新生血管市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國脈絡膜新生血管市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Regeneron Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
    • Sanwa Kagaku Kenkyusho Co. Ltd.
Product Code: MRR-976C0ED91BDE

The Choroidal Neovascularization Market is projected to grow by USD 11.69 billion at a CAGR of 7.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.38 billion
Estimated Year [2025] USD 6.88 billion
Forecast Year [2032] USD 11.69 billion
CAGR (%) 7.85%

A clear and comprehensive introduction to choroidal neovascularization that frames clinical characteristics, diagnostic improvements, and the evolving treatment landscape

Choroidal neovascularization (CNV) remains one of the most consequential complications affecting the choroid-retina interface, with implications for vision loss, long-term morbidity, and healthcare resource allocation. This introduction distills the clinical characteristics, diagnostic pathways, and contemporary standards of care that frame the therapeutic and commercial environment. Advances in multimodal imaging and earlier detection have reshaped patient journeys, enabling more timely interventions that alter disease trajectories and patient outcomes. These diagnostic gains, however, have increased the complexity of care coordination among ophthalmologists, retinal specialists, and ambulatory surgical centers.

Concurrently, treatment paradigms have evolved from focal therapies toward sustained biologic modulation of angiogenic pathways. Anti-VEGF agents have become central to clinical practice, while adjunctive approaches, including combination regimens and photodynamic therapy, persist in specific phenotypes or refractory cases. Payer policies and reimbursement coding have not always moved in lockstep with clinical innovation, creating variability in access and treatment continuity. As a result, stakeholders must navigate an intricate interplay between therapeutic efficacy, delivery logistics, and economic considerations when designing clinical programs and commercial strategies. This overview establishes the clinical and operational context necessary to evaluate subsequent sections on market shifts, segmentation insights, and strategic recommendations.

An interdisciplinary view of transformative scientific, clinical, and delivery-model shifts reshaping CNV treatment paradigms and stakeholder expectations

The landscape for CNV treatment is experiencing transformative shifts driven by scientific innovation, changing care delivery models, and a renewed focus on patient-centric outcomes. Biologic refinement and molecular engineering of anti-VEGF agents have extended durability and modified safety profiles, prompting clinicians to rethink dosing intervals and follow-up regimens. At the same time, real-world evidence and registry-driven insights are informing more nuanced therapy selection, especially for patients with complex lesion morphologies or those who demonstrate suboptimal response to first-line agents. These clinical dynamics are intersecting with operational changes: ambulatory surgical centers and ophthalmology clinics are increasingly equipped to deliver complex intravitreal therapies, while hospital systems continue to play a central role for higher-acuity presentations.

In parallel, payer scrutiny and value-based contracting conversations are influencing formulary positioning and access pathways. Manufacturers are responding with differentiated patient support programs and innovative distribution partnerships to reduce barriers to adherence. Technological advances in imaging and telemedicine have further enabled remote monitoring, which can reduce patient burden and improve adherence, but also require investment in interoperable systems and clinician training. Taken together, these shifts demand cross-functional strategies that align clinical differentiation, supply chain reliability, and stakeholder engagement to capitalize on therapeutic advances while safeguarding patient access and continuity of care.

A strategic analysis of how the 2025 United States tariff environment is reshaping supply chain resilience, manufacturing footprints, and commercial contracting for CNV therapies

The cumulative impact of United States tariff changes in 2025 is altering cost structures and supply chain dynamics that underpin CNV therapeutics and related medical devices. Tariff adjustments on imported biologic components, packaging materials, and specialized delivery devices have elevated sourcing costs for certain manufacturers, prompting them to reassess procurement strategies. As a result, some firms are accelerating initiatives to localize critical steps of biologic manufacturing or to diversify supplier bases across multiple geographies to mitigate exposure to trade policy volatility. This reconfiguration of supply chains can increase lead times and create short-term inventory imbalances that require proactive inventory and distribution planning.

Moreover, tariff-driven cost pressures are influencing the calculus around pricing, patient assistance programs, and contracting with payers. Health systems and distributors may face incremental logistical costs that translate into negotiations over reimbursement and formulary placement. In response, manufacturers are exploring near-term tactics such as hedging procurement contracts, modifying packaging to reduce tariffable components, and investing in regional fill-and-finish capacity. While these steps can stabilize supply, they also require capital allocation and regulatory alignment. Ultimately, the tariff environment is accelerating strategic decisions around manufacturing footprint, commercial contracting, and collaboration with end users to preserve timely access for patients while maintaining sustainable commercial models.

Deep segmentation insights linking treatment types, molecular classes, lesion and disease phenotypes, care settings, and distribution pathways to actionable clinical and commercial strategies

Segmentation analysis reveals how therapeutic choices, molecular classes, clinical presentations, lesion characteristics, lines of therapy, distribution channels, and end-user types collectively shape demand dynamics and care pathways. Treatment type remains a primary axis: anti-VEGF therapy dominates therapeutic decision-making, with molecule-level differentiation among agents such as aflibercept and ranibizumab that influence dosing cadence and patient follow-up. Bevacizumab retains relevance through cost-driven use in certain settings, while newer entrants with modified molecular structures aim to extend durability or alter safety profiles. Combination approaches that integrate photodynamic therapy with anti-VEGF agents are selectively employed for specific refractory or atypical presentations, and standalone photodynamic therapy, anchored by verteporfin, maintains a role in certain lesion subtypes.

Drug class segmentation highlights the operational and regulatory differences between fusion proteins and monoclonal antibodies; manufacturing complexity, cold-chain requirements, and patent landscapes differ across these classes and inform commercialization strategies. Disease-type distinctions between neovascular age-related macular degeneration and pathologic myopia dictate patient populations, natural history, and therapeutic responsiveness, requiring tailored clinical protocols. Lesion-type categories such as classic, mixed, and occult choroidal neovascularization present unique prognostic and treatment-response considerations that clinicians factor into initial therapy selection and monitoring frequency. Line-of-therapy segmentation underscores differences in goals between first-line interventions aimed at rapid disease control and second- or third-line approaches focused on refractory disease management. Distribution channel nuances between hospital and retail pharmacies affect dispensing workflows, reimbursement processes, and patient access points. Finally, end-user segmentation-spanning ambulatory surgical centers, hospitals, and ophthalmology clinics-captures the diversity of care settings where CNV treatments are delivered, each with distinct operational constraints, clinician expertise, and patient throughput considerations. Synthesizing these segmentation layers enables stakeholders to align clinical trial design, commercial messaging, and service delivery models to specific patient and provider contexts.

Regional strategic perspectives that reconcile clinical practice diversity, regulatory variation, and supply chain realities across major global healthcare regions for CNV

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market evolution is shaped by advanced retinal care infrastructure and strong adoption of innovation in urban centers, while payer complexity and heterogeneous reimbursement policies create variable access pathways and necessitate tailored market access strategies. In contrast, Europe, Middle East & Africa encompasses diverse regulatory regimes and healthcare financing models, with some markets demonstrating rapid uptake of advanced biologics and others constrained by budget ceilings; these differences require nuanced country-level engagement and evidence generation to support reimbursement dossiers. Asia-Pacific presents a heterogeneous landscape where high-volume patient populations and growing specialist capacity coexist with differences in procurement practices, pricing sensitivity, and regulatory timelines; local manufacturing and regional partnerships can be decisive factors in commercial success.

Across these regions, differences in clinical practice patterns, imaging availability, and end-user capabilities influence treatment pathways and patient outcomes. Regional regulatory policies around biologics, biosimilars, and import controls interact with logistical realities to shape supply chain design and launch sequencing. Therefore, stakeholders must adopt regionally differentiated strategies that integrate health-economic evidence, local real-world data, and clinician engagement plans to ensure that therapeutic innovations translate into sustained clinical adoption and patient benefits.

Company-level competitive dynamics emphasizing molecular innovation, real-world evidence, patient support, and supply chain resilience as bases for differentiation in CNV

Key company-level dynamics center on innovation in molecule design, lifecycle management, and patient support infrastructure. Developers are advancing next-generation anti-VEGF agents that seek to extend durability, optimize safety, and differentiate via unique mechanisms or delivery formats. Strategic priorities include building robust real-world evidence programs to demonstrate comparative effectiveness, establishing comprehensive patient support and adherence services, and investing in manufacturing redundancy to reduce supply risk. Partnerships between innovator firms and specialty distributors or hospital systems are becoming more salient as companies seek to streamline product access and overcome logistical hurdles tied to complex biologic handling.

Competitive differentiation increasingly depends on the ability to demonstrate outcomes in varied lesion types and patient subsets, to engage payers through outcome-based arrangements, and to enable clinicians with practical tools for treatment decisions and imaging interpretation. Companies that successfully integrate clinical development with targeted health-economic data and that invest in scalable support programs for diverse care settings are best positioned to navigate reimbursement negotiations and to sustain adoption in the face of biosimilar or alternative therapeutic entrants. Observing these company behaviors provides a roadmap for supply chain investment, evidence-generation priorities, and commercial execution.

Actionable, prioritized recommendations for industry leaders to align evidence generation, manufacturing resilience, access programs, and payer engagement for CNV success

To translate the report's insights into operational advantage, industry leaders should prioritize a set of actionable initiatives that align clinical differentiation with commercial execution. First, concentrate evidence-generation efforts on head-to-head and real-world comparative studies that clarify therapeutic positioning across lesion subtypes and lines of therapy; such evidence will improve payer dialogues and clinician confidence. Second, invest in flexible manufacturing and regional fill-and-finish capabilities to reduce exposure to tariff-driven disruptions and to shorten lead times for critical supplies. Third, tailor access and patient support programs to the realities of different distribution channels and end users, ensuring that ambulatory surgical centers and ophthalmology clinics receive logistical and educational support to optimize adherence and outcomes.

Additionally, explore innovative contracting models with payers that tie reimbursement to measurable clinical outcomes, and deploy digital monitoring tools to support remote follow-up and adherence. Foster targeted partnerships with regional stakeholders to address regulatory and procurement heterogeneity, and design product launch sequencing that reflects regional readiness and infrastructure capacity. Finally, translate clinical differentiation into pragmatic clinician-facing resources-such as dosing algorithms and imaging interpretation guides-to reduce variation in care and to accelerate adoption in complex patient populations.

A rigorous, mixed-methods research methodology combining primary stakeholder interviews and systematic secondary evidence review with robust triangulation and quality controls

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure robustness, validity, and practical relevance. Primary research involved semi-structured interviews with retina specialists, hospital pharmacy directors, clinic administrators, and payers to capture firsthand perspectives on treatment decision-making, operational constraints, and access challenges. Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and publicly available guidance from professional societies to map treatment paradigms and lesion-specific outcomes. Data triangulation combined qualitative insights with published clinical evidence to validate emergent themes and to surface discrepancies between clinical trial populations and real-world practice.

Quality control measures included cross-validation of interview findings across multiple stakeholder cohorts, transparent documentation of inclusion criteria for secondary sources, and sensitivity checks to assess the robustness of strategic conclusions. The methodology explicitly acknowledges limitations related to regional heterogeneity and evolving regulatory landscapes; where data gaps exist, the analysis highlights areas requiring further primary evidence generation. Ethical standards for primary research were maintained, with informed consent obtained for interviews and confidentiality assured for proprietary disclosures. This mixed-methods approach supports a balanced, evidence-informed perspective that is actionable for clinical, commercial, and policy stakeholders.

A conclusive synthesis of clinical innovation, operational resilience, and payer-aligned strategies to convert therapeutic advances in CNV into sustained patient and commercial outcomes

In conclusion, choroidal neovascularization remains a domain of rapid scientific and commercial evolution where clinical innovation, supply chain strategy, and payer engagement intersect to determine patient access and therapeutic success. Advances in anti-VEGF biology and adjunctive therapies are enabling more personalized treatment paradigms, but these opportunities must be matched by investments in evidence generation, manufacturing resilience, and targeted access programs. Tariff dynamics and regional regulatory complexity add layers of operational risk that companies can mitigate through diversified sourcing, regional partnerships, and proactive payer strategies.

Ultimately, organizations that synchronize clinical differentiation with pragmatic execution-through rigorous real-world studies, clinician-enabled adoption tools, and flexible commercial models-will achieve sustained adoption and deliver measurable patient benefit. The strategic recommendations and segmentation insights presented herein provide a framework to prioritize initiatives, align cross-functional teams, and convert clinical promise into enduring therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence image analysis in early CNV detection and monitoring
  • 5.2. Development of sustained-release intravitreal implants to reduce treatment burden in CNV patients
  • 5.3. Emergence of gene editing therapies targeting vascular endothelial growth factor pathways for CNV
  • 5.4. Increasing uptake of biosimilar anti-VEGF agents to improve affordability and access for CNV care
  • 5.5. Adoption of teleophthalmology platforms for remote monitoring and management of CNV progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Choroidal Neovascularization Market, by Treatment Type

  • 8.1. Anti-Vegf Therapy
    • 8.1.1. Aflibercept
    • 8.1.2. Bevacizumab
    • 8.1.3. Brolucizumab
    • 8.1.4. Conbercept
    • 8.1.5. Ranibizumab
  • 8.2. Combination Therapy
    • 8.2.1. Photodynamic + Anti-Vegf
  • 8.3. Photodynamic Therapy
    • 8.3.1. Verteporfin

9. Choroidal Neovascularization Market, by Drug Class

  • 9.1. Fusion Proteins
  • 9.2. Monoclonal Antibodies

10. Choroidal Neovascularization Market, by Disease Type

  • 10.1. Neovascular Amd
  • 10.2. Pathologic Myopia

11. Choroidal Neovascularization Market, by Lesion Type

  • 11.1. Classic Cnv
  • 11.2. Mixed Cnv
  • 11.3. Occult Cnv

12. Choroidal Neovascularization Market, by Line Of Therapy

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Line

13. Choroidal Neovascularization Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy

14. Choroidal Neovascularization Market, by End User

  • 14.1. Ambulatory Surgical Centers
  • 14.2. Hospitals
  • 14.3. Ophthalmology Clinics

15. Choroidal Neovascularization Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Choroidal Neovascularization Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Choroidal Neovascularization Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Regeneron Pharmaceuticals, Inc.
    • 18.3.2. F. Hoffmann-La Roche Ltd
    • 18.3.3. Novartis AG
    • 18.3.4. Bayer AG
    • 18.3.5. Sanwa Kagaku Kenkyusho Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHOROIDAL NEOVASCULARIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (